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Background: A few studies have shown an association between blood group alleles and vascular disease,
including atherosclerosis, which is thought to be due to the higher level of von Willebrand factor in these
individuals and the association of blood group locus variants with plasma lipid levels. No large population-based
study has explored this association with overall and cause-specific mortality.
Methods: We aimed to study the association between ABO blood groups and overall and cause-specific mortality
in the Golestan Cohort Study. In this cohort, 50,045 people 40- to 70-years old were recruited between 2004 and
2008, and followed annually to capture all incident cancers and deaths due to any cause. We used Cox regression
models adjusted for age, sex, smoking, socioeconomic status, ethnicity, place of residence, education and opium use.
Results: During a total of 346,708 person-years of follow-up (mean duration 6.9 years), 3,623 cohort participants died.
Non-O blood groups were associated with significantly increased total mortality (hazard ratio (HR) = 1.09; 95%
confidence interval (CI): 1.01 to 1.17) and cardiovascular disease mortality (HR = 1.15; 95% CI: 1.03 to 1.27). Blood
group was not significantly associated with overall cancer mortality, but people with group A, group B, and all
non-O blood groups combined had increased risk of incident gastric cancer. In a subgroup of cohort participants, we
also showed higher plasma total cholesterol and low-density lipoprotein (LDL) in those with blood group A.
Conclusions: Non-O blood groups have an increased mortality, particularly due to cardiovascular diseases, which may
be due to the effect of blood group alleles on blood biochemistry or their effect on von Willebrand factor and factor
VIII levels.
Please see related commentary http://dx.doi.org/10.1186/s12916-014-0250-y.
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E.B. Ford, the renowned geneticist, was quoted in 1945
as saying, ‘It is reasonable to conclude, from what we
know of polymorphisms, that individuals belonging to
the different blood groups are not equally viable…’ [1].
Although blood group antigens have been widely recog-
nized because of the complications they produce in
transfusion medicine [2], their conservation through* Correspondence: arash.etemadi@nih.gov
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unless otherwise stated.evolution and their presence on many cells in the
human body [1] suggest they are also critical to human
physiology. However, the only documented roles, so
far, include susceptibility to certain infections such as
Plasmodium falciparum [3] and Helicobacter pylori [4],
and the level and structure of the von Willebrand Factor
(vWF)-FVIII complex in blood [2].
The ABO(H) blood group system was the first genetic
polymorphism discovered in humans [5]. So, it is not
surprising that it has been studied in the context of
many chronic diseases. Many vascular disorders (espe-
cially venous thromboembolism and atherosclerotic dis-
ease) have been linked to non-O blood group status [6].
This association is thought to be mainly due to the
higher level of factor VIII and vWF in these individuals,l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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variants with plasma lipid levels, especially cholesterol
[7]. Higher levels of factor VIII and vWF lead to in-
creased thrombotic tendency [8], and plasma cholesterol
is a known risk factor for atherosclerosis. ABO blood
groups have also been extensively studied in association
with cancer. Some of the most consistent associations
observed so far include the associations between non-O
blood groups and pancreatic cancer (which was also
confirmed in a genome-wide association study (GWAS)
[9]), and between the A blood group and gastric cancer
[10] and atrophic gastritis [11].
Despite their discovery in 1900, the critical role of
ABO blood groups in transfusion medicine, and their
apparent link to multiple diseases, the association of
blood groups with mortality in the general population
has not been evaluated in a large prospective study [6].
Therefore, we decided to examine the hypothesis that
blood groups are associated with overall and cause-
specific mortality, using the data from the large pro-
spective Golestan Cohort Study.
Methods
Details of the Golestan Cohort Study (GCS) have been
published before [12]. This study is a population-based
cohort in northeastern Iran which has followed 50,045
people above the age of 40 since 2004. At cohort recruit-
ment, between the years 2004 and 2008, all participants
were interviewed by trained cohort staff and underwent
blood group determination. ABO blood group and Rh
could not be determined for four and two individuals,
respectively, who were excluded from analyses.
The GCS was approved by the Institutional Review
Boards of the Digestive Disease Research Center
(DDRC), the US National Cancer Institute (NCI), and
the International Agency for Research on Cancer
(IARC), and all participants gave written informed
consent before enrollment.
Details of the GCS follow-up procedures have been
published before [13]. Annual follow-up has had a 99%
success rate so far. In these follow-up contacts, any
case that is suspicious for cancer is evaluated and docu-
mented, and the records are complemented by linkage
to local and national registries. Any reported death is
also followed by a visit from a physician who completes
a verbal autopsy questionnaire, validated for this popula-
tion [13], by interviewing the closest relative of the
deceased. At the same time, death certificates and all
available medical documents are collected. The cause of
death is classified according to the International Classifi-
cation of Diseases, 10th revision (ICD-10) codes. For this
analysis, causes of death were categorized as medical or
external (that is, accidents, intoxication, suicide or other
types of injury). Medical causes of death were furtherdivided into cardiovascular disease (ischemic heart dis-
ease (ICD-10 codes I20-I25), cerebrovascular disease
(I60-I69), and other diseases of the circulatory system);
death due to cancer (ICD-10 codes C00-C97); and death
due to other medical causes. Follow-up for this analysis
continued until the subject was lost to follow-up, death
occurred, or 28 February 2014, whichever came first.
In a random subgroup of the original cohort (n =
11,418), a second round of risk factor assessment and
blood biochemistry tests was done four to five years after
the initial enrollment. These results were used to analyze
the association of blood groups with cardiovascular risk
factors, including plasma lipids, blood glucose, blood
pressure and anthropometric measurements.
We used Cox proportional hazards models, with age
as the time variable, to estimate unadjusted and adjusted
hazard ratios (HRs) and 95% confidence intervals (CIs)
for mortality and cancer incidence, in relation to blood
groups. Participants were left-censored at the age of en-
rollment, and all models (crude or adjusted) were ad-
justed for age at cohort baseline. The adjusted models
also included potential confounders (sex, ethnicity, place
of residence (urban or rural), education, quartiles of
smoking in pack-years, opium use and an index of socio-
economic status [14]). These variables were selected
because they have been shown to affect mortality in gen-
eral or in this population [15]. Models for cancer inci-
dence were adjusted for the same variables. The cancers
used as outcomes were those having strong a priori as-
sociations with blood groups (gastric and pancreatic
cancer) and the most common cancer in this population
(esophageal squamous cell carcinoma). The follow up
for these models continued until the loss to follow-up,
death, cancer diagnosis, or 28 February 2014, whichever
came first.
Population attributable fractions (AFp) were calculated
using Levin’s formula [16]:
AFp ¼ RR−1f g  PF11þ RR−1f gPF1
where PF1 is the proportion of the population in any
given blood group, and RR is the relative risk of the out-
come in that blood group compared with the reference
risk (group O).
All statistical tests were two-sided and a P value of
0.05 or smaller was considered significant.
Results
The most common blood group phenotype in this popu-
lation was A (33.4%) followed by O (29.9%), and 93.5%
were Rh positive. Table 1 shows the characteristics of
the population across different blood groups. During a
total of 346,708 person-years of follow-up (mean ± SD:













Sex female 8738 (58.4) 9555 (57.2) 7760 (57.2) 2757 (57.3) 26974 (57.6) 1837 (56.7)
male 6233 (41.6) 7150 (42.8) 5795 (42.8) 2053 (42.7) 19831 (42.4) 1401 (43.3)
Agea 52.1 (9) 52.1 (9) 52.2 (9.1) 52.1 (9) 52.1 (9.0) 52.2 (8.9)
Ethnicity Turkmen 10836 (72.4) 12677 (75.9) 10033 (74) 3705 (77) 35060 (74.9) 2192 (67.7)
non-
Turkmen
4135 (27.6) 4028 (24.1) 3522 (26) 1105 (23) 11745 (25.1) 1046 (32.3)
Residence urban 3022 (20.2) 3257 (19.5) 2794 (20.6) 955 (19.9) 9247 (19.8) 783 (24.2)
rural 11949 (79.8) 13448 (80.5) 10761 (79.4) 3855 (80.1) 37558 (80.2) 2455 (75.8)
Education none 10388 (69.4) 11785 (70.5) 9514 (70.2) 3431 (71.3) 32919 (70.3) 2199 (67.9)
Up to
8 years
3246 (21.7) 3547 (21.2) 2910 (21.5) 1004 (20.9) 9985 (21.3) 723 (22.3)
High school 993 (6.6) 1019 (6.1) 855 (6.3) 288 (6) 2929 (6.3) 226 (7)
University 344 (2.3) 354 (2.1) 276 (2) 87 (1.8) 972 (2.1) 90 (2.8)
Smoking
pack-year
Non-smoker 11751 (78.5) 13149 (78.7) 10581 (78.1) 3753 (78) 36685 (78.4) 2551 (78.8)
Q1 (≤3) 858 (5.7) 934 (5.6) 783 (5.8) 272 (5.7) 2682 (5.7) 165 (5.1)
Q2 (3 to 10) 772 (5.2) 880 (5.3) 695 (5.1) 233 (4.8) 2406 (5.1) 174 (5.4)
Q3( 10 to 24) 820 (5.5) 900 (5.4) 757 (5.6) 289 (6) 2581 (5.5) 185 (5.7)
Q4 (>24) 770 (5.1) 842 (5) 739 (5.5) 263 (5.5) 2451 (5.2) 163 (5)
Opium use 2535 (16.9) 2854 (17.1) 2306 (17) 804 (16.7) 7977 (17) 523 (16.2)
Socioeconomic
status
Low 4065 (27.2) 4703 (28.2) 3803 (28.1) 1366 (28.4) 13054 (27.9) 884 (27.3)
Low-middle 3268 (21.8) 3699 (22.1) 3092 (22.8) 1085 (22.6) 10464 (22.4) 680 (21)
High-middle 3740 (25) 4286 (25.7) 3392 (25) 1167 (24.3) 11792 (25.2) 793 (24.5)
High 3898 (26) 4017 (24) 3268 (24.1) 1192 (24.8) 11495 (24.6) 881 (27.2)
Medical history
at baseline
CVD 959 (6.4) 1007 (6) 803 (5.9) 282 (5.9) 2834 (6.1) 217 (6.7)
Hypertension 2968 (19.8) 3284 (19.7) 2726 (20.1) 896 (18.6) 9264 (19.8) 611 (18.9)
DM 999 (6.7) 1178 (7.1) 952 (7) 325 (6.8) 3224 (6.9) 230 (7.1)
Cancer 52 (0.4) 56 (0.3) 34 (0.3) 17 (0.4) 149 (0.3) 10 (0.3)
aNumbers show frequencies (percentage) except for age which is mean (SD). CVD, cardiovascular disease; DM, diabetes mellitus.
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ticipants died. The most common cause of death was
cardiovascular disease (n = 1,879, 51.9%), followed by
cancer (n = 775, 21.4%).
For mortality analyses, 209 deaths due to external
causes were excluded, and only medical causes of death
were considered. As Table 2 shows, non-O blood groups
were associated with a significantly increased total mor-
tality (HR = 1.09; 95% CI: 1.01 to 1.17), which was most
pronounced for cardiovascular disease mortality (HR =
1.15; 95% CI: 1.03 to 1.27). In this population, 5.9% of
total mortality due to medical causes, and 8.9% of those
due to cardiovascular disease could be attributed to hav-
ing non-O blood group. Among the different non-O
blood groups, both groups A and B were individually
associated with both higher overall and cardiovascular
mortality, compared with group O. Cancer mortality
was, to some extent, more frequent in individuals withnon-O blood group alleles, although this difference was
not statistically significant.
People with a non-O blood group had an increased
risk of gastric cancer (HR = 1.55; 95% CI: 1.09 to 2.21).
The significantly increased risk was seen in both blood
group A (HR = 1.57; 95% CI: 1.06 to 2.32) and B (HR =
1.59; 95% CI: 1.06 to 2.39). Other cancers were not asso-
ciated with blood group phenotype (Table 3).
Absence of the D antigen of Rhesus (Rh) blood group
(Rh-) was less common in Turkmen than in non-Turkmen
(5.9% versus 8.2%), but there was no association between
Rh positivity and any of the study outcomes. We also tested
the interaction between Rh group and ABO blood type,
and the results were not significant (data not shown). In a
subgroup of 11,418, for whom biochemistry test results
were available, the association between cardiovascular risk
factors and ABO blood groups was assessed. As Table 4
shows, compared with blood group O, group A was



















adjusted HR (95% CI) adjusted HR (95% CI) adjusted HR (95% CI)
O 14,971 (103,756) 1,007 (971) 1 1 1 1 1
A 16,705 (115,764) 1,223 (1,056) 1.11 (1.02,1.21)* 1.08 (1.00,1.18)* 1.12 (1.00,1.26)* 1.05 (0.87,1.25) 1.03 (0.86,1.23)
B 13,555 (93,740) 1,036 (1,105) 1.12 (1.03,1.23)* 1.09 (1.00,1.20)* 1.15 (1.02,1.30)* 1.14 (0.95,1.38) 0.91 (0.75,1.10)
AB 4,810 (33,434) 357 (1,068) 1.10 (0.97,1.25) 1.07 (0.95,1.22) 1.16 (0.98,1.37) 1.03 (0.79,1.35) 0.92 (0.70, 1.21)
Non-O 35,070 (242,966) 2,616 (1,077) 1.11 (1.03,1.20)* 1.09 (1.01,1.17)* 1.15 (1.03,1.27)** 1.08 (0.92,1.27) 0.97 (0.83,1.13)
Rh+ 46,803 (324,155) 3,381 (1,043) 1 1 1 1 1
Rh- 3,238 (22,553) 242 (1,073) 1.04 (0.91,1.19) 1.06 (0.93,1.21) 1.04 (0.87,1.25) 0.88 (0.64,1.19) 1.30 (0.99,1.69)
aExcluding deaths due to accidents, intoxication, suicide or other types of injury; bCox regression models adjusted for age, smoking, socioeconomic status,
ethnicity, residence, education, and opium use. *P <0.05, **P <0.01, CI, confidence ratio; CVD, cardiovascular disease; HR: hazard ratio; MR: mortality rate per
100,000 person-years.
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lipoprotein (LDL), while group B had lower lipid levels. In
total, the only significant difference between non-O and O
groups was higher blood glucose in the former (Table 4).
Discussion
Our results show that individuals with non-O blood
groups have higher overall and cardiovascular mortality.
They also demonstrate an association between group A
and B blood groups and gastric cancer.
The association of non-O blood groups with the inci-
dence of different vascular diseases has been known for
some time, although there has been some controversy
because of the paucity of information from large pro-
spective studies [17]. In one of the few such studies
before the current report, the combined analysis of the
Nurses’ Health Study and the Health Professionals
Follow-up Study, 6.27% of the coronary heart disease
(CHD) cases were attributable to non-O blood groups
[7]. However, this study did not report all-cause or
cardiovascular mortality. In another study, among 4,901
patients with ischemic heart disease, those with non-O
blood groups had higher cardiac mortality [18]. Non-O




Number of cases adjusted HRa (95% CI) Number of cases
O 39 1 69
A 73 1.57 (1.06,2.32)* 67
B 58 1.59 (1.06,2.39)* 62
AB 18 1.35 (0.77,2.36) 18
Non-O 149 1.55 (1.09,2.21)** 147
Rh+ 170 1 206
Rh- 18 1.57 (0.97,2.56) 10
aCox regression models adjusted for age, smoking, socioeconomic status, ethnicity,
*P <0.05, **P <0.01. CI, confidence interval; ESCC: esophageal squamous cell carcinocoronary artery disease [19], more extensive myocardial
necrosis and visible thrombus [20]. The two main mech-
anisms proposed for these associations include the effect
of ABO blood groups on serum cholesterol and their in-
fluence on hemostasis [8]. Some studies have shown
an association between non-O blood groups, particularly
group A, and hypercholesterolemia [21], while others
have failed to show such an association [22]. The associ-
ation of variation at the ABO blood group locus with
plasma lipid levels has been seen in a GWAS of more
than 100,000 individuals of European descent [23]. We
also observed higher total cholesterol and LDL levels in
people with blood group A, but we think that this alone
cannot explain the increased mortality among non-O
blood groups mainly because, compared with blood
group O, plasma lipid levels were only higher in group
A, and these levels were actually lower in other non-O
blood types. A recent study also estimated that about
10% of the CHD risk associated with non-O blood
groups, is mediated by its influence on LDL cholesterol
levels [24].
The association of non-O blood groups with cardiovas-
cular mortality may also be due to the higher levels of
vWF and factor VIII in these individuals [8]. A GWASin the Golestan Cohort Study
Pancreatic cancer
adjusted HR (95% CI) Number of cases adjusted HR (95% CI)
1 20 1
0.82 (0.58,1.15) 21 0.91 (0.49,1.68)
0.94 (0.67,1.32) 13 0.70 (0.35,1.42)
0.76 (0.45,1.27) 5 0.75 (0.28,2.00)
0.86 (0.64,1.14) 39 0.81 (0.47,1.39)
1 53 1
0.74 (0.39,1.39) 6 1.70 (0.73,3.96)
residence, education, and opium use.
ma; HR: hazard ratio; MR: mortality rate per 100,000 person-years.
Table 4 Cardiovascular risk factors in a random subgroup (n = 11,418) of Golestan Cohort Study participants according
to blood group phenotype
Variable Blood group
O (number = 3,489) A (number = 3,738) B (number = 3,089) AB (number = 1,102) Non-O (number = 7,929)
Total cholesterola 202.9 (43.5) 205.6 (43.8)** 200.5 (41.7)* 201.0 (41.3) 203.0 (42.7)
HDL 59.4 (14.8) 59.9 (14.8) 59.2 (14.4) 59.1 (14.5) 59.5 (14.6)
LDL 116.2 (36.1) 118.8 (35.4)** 114.2 (34.4)* 115.9 (34.5) 116.6 (35.0)
Triglycerides 139.8 (98.3) 139.2 (102.0) 139.3 (98.9) 132.3 (77.9)* 138.3 (97.8)
FBG 103.7 (39.5) 105.6 (41.1) 104.8 (40.7) 106.0 (45.3)* 105.4 (41.6)*
Systolic blood pressure 125.8 (20.9) 125.7 (20.6) 125.7 (21.0) 124.9 (20.5) 125.6 (20.8)
Diastolic blood pressure 77.8 (12.5) 77.4 (12.5) 77.5 (12.6) 77.7 (12.4) 77.5 (12.5)
BMI 27.1 (5.3) 27.1 (5.3) 27.1 (5.4) 27.0 (5.3) 27.1 (5.3)
Waist circumference 94.6 (13.8) 94.6 (13.8) 94.6 (14.1) 94.2 (14.0) 94.5 (13.9)
aNumbers are mean (standard deviation). *P <0.05, **P < 0.01. P values adjusted for age, sex, place of residence, education, smoking in pack-years, opium use,
and socioeconomic status. Blood lipids and glucose models were also adjusted for BMI. BMI: body mass index; FBG: fasting blood glucose; HDL: high-density
lipoproteins; LDL: low-density lipoproteins.
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myocardial infarction in patients with angiographic
coronary artery disease (CAD), and concluded that the
variation linked to group O and reduced vWF, was
protective against myocardial infarction in CAD pa-
tients [25]. vWF levels are approximately 25% to 30%
higher in people with non-O blood groups [2]. This ef-
fect is a direct functional effect and is not due to an
association of ABO locus with another gene [26], and
the ABH antigenic structures are present on the circu-
lating vWF [2]. Higher levels of vWF have been shown
to be independently associated with increased cardio-
vascular and all-cause-mortality in humans [27], and
atherosclerotic plaque progression in mice [28]. The
reasons for this association may be the direct role of
vWF in platelet adhesion, aggregation and thrombo-
genesis, although some investigators believe that other
mechanisms might be involved as well [29].
Evidence suggests that blood groups A, B and AB
probably have a similar effect on the circulating vWF.
[30] Blood group A consists of two major subgroups,
A1 (about 80%) and A2 (about 20%). In this study, we
did not check for differentiation between these sub-
types. However, it has been reported that A2 blood
group has approximately 47% lower risk of venous
thromboembolism compared to other non-O blood
groups [31,32]. This lower risk has been suggested
to be caused by decreased glycosylation of H antigen,
due to a 30- to 50-fold lower glycosyltransferase activ-
ity associated with the A2 allele compared to the A1
allele [33]. The impact of such differences on CVD
risk and mortality is not clear.
To the best of our knowledge, this is the first study to
investigate ABO blood group in relation to cancer mor-
tality, and unlike CVD mortality, we did not observe a
significant association for mortality due to all cancerscombined. However, incident gastric cancer, which is
the second most common cancer in our population,
was associated with both blood groups A and B. The
association of gastric cancer with blood group A has
been observed in many previous studies [10] and is
thought to be linked to an altered inflammatory re-
sponse to Helicobacter pylori, particularly cagA posi-
tive strains [4]. In the largest study so far, a 35-year
follow-up of one million Swedish and Danish blood
donors showed an increased risk of gastric cancer
among individuals with blood group A compared to
group O [34]. However, most previous reports have
shown risk estimates of around 1.2 [6], while we ob-
served a stronger association. Our study is also one of
the few studies to show an association between blood
group B and gastric cancer [11].
One limitation of our study is the left censoring
of the mortality data, although most deaths in our
population before age 40 (our cohort’s minimum
enrollment age) are due to accidents which were not
the focus of our evaluation [35]. Also, there were not
enough events in the subgroup with available bio-
chemistry data (because of the short follow-up dur-
ation in this subgroup), to allow direct analysis of the
mediation effect of biochemical changes in the ABO-
mortality association.
Conclusions
We showed that, in apparently healthy individuals, 5.9%
of total deaths due to medical causes and 8.9% of cardio-
vascular deaths were attributable to having non-O blood
groups, and these blood groups were also associated
with a higher risk of gastric cancer. These findings sup-
port the clinical importance of blood group determin-
ation in assessing health risks beyond its application in
transfusion medicine.
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